Drug intelligence / Profile preview

BAC

Development stage: Unknown
Lead developer: Charsire Biotechnology
Administration: Topical

Overview

BAC (Multi-Glycan Complex) is a topical therapeutic candidate developed by Charsire Biotechnology Corp. for the treatment of Alzheimer's disease and vascular dementia. It consists of a proprietary mixture of glycans derived from botanical sources, designed to improve cerebral microcirculation and provide neuroprotective effects. Unlike traditional dementia treatments that are administered orally or via injection, BAC is applied topically to the skin (typically the neck area over the carotid arteries), aiming to enhance blood flow to the brain and support neuronal health through a non-invasive delivery mechanism. The drug has been evaluated in Phase II clinical trials to assess its safety and efficacy in improving cognitive function in patients with dementia.

Other names: Multi-Glycan Complex

Beyond the preview

Go deeper on BAC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAC.

Explore the full profile